Opinion
Video
From Papillary to CIS: Tailoring NMIBC Treatment
Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer.
Physician Summary:
Specific tumor features—such as papillary architecture and the presence of carcinoma in situ (CIS)—play a critical role in shaping treatment decisions for NMIBC. Papillary tumors, particularly low-grade Ta lesions, often warrant a more conservative approach with surveillance and possible intravesical therapy. In contrast, CIS, due to its flat, high-grade, and aggressive nature, typically necessitates prompt and intensive treatment, often with BCG immunotherapy. Recognizing these distinctions is essential for risk-adapted management, enabling clinicians to balance efficacy with the potential risks of overtreatment or undertreatment.
